Patents by Inventor Christopher Lazarski

Christopher Lazarski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C-carbon linked glutarimide degronimers for target protein degradation
    Patent number: 11992531
    Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: May 28, 2024
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
  • EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS
    Publication number: 20240158418
    Abstract: The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent.
    Type: Application
    Filed: November 21, 2023
    Publication date: May 16, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
    Publication number: 20240076300
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: May 8, 2023
    Publication date: March 7, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • CYTOKINE COCKTAILS FOR SELECTIVE EXPANSION OF T CELL SUBSETS
    Publication number: 20220160767
    Abstract: The disclosure relates to methods of culturing and expanding CD4+ and/or CD8+ T cells in culture. In some embodiments, the methods include expanding, proliferating and storing lymphocytes in tissue culture by exposing the lymphocytes to a combination of cytokines and/or nucleic acids expressing cytokines or functional fragments or variants thereof. The disclosure further relates to methods of generating and manufacturing CD4+ and/or CD8+ T cells that are specific to one or a plurality of viral antigens.
    Type: Application
    Filed: November 30, 2021
    Publication date: May 26, 2022
    Applicant: CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Patrick HANLEY, Christopher LAZARSKI, Michael KELLER, Catherine BOLLARD
  • HERPES SIMPLEX VIRUS VACCINE
    Publication number: 20190100561
    Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
    Type: Application
    Filed: October 10, 2018
    Publication date: April 4, 2019
    Applicant: GenVec, Inc.
    Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
  • Herpes simplex virus vaccine
    Patent number: 10125174
    Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: November 13, 2018
    Assignee: GenVec, Inc.
    Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
  • HERPES SIMPLEX VIRUS VACCINE
    Publication number: 20170275339
    Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
    Type: Application
    Filed: June 9, 2017
    Publication date: September 28, 2017
    Applicant: GenVec, Inc.
    Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
  • Herpes simplex virus vaccine
    Patent number: 9676824
    Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: June 13, 2017
    Assignee: GenVec, Inc.
    Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
  • HERPES SIMPLEX VIRUS VACCINE
    Publication number: 20150140025
    Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski